Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|March 11, 2021
Vial Crimping Machines for R&D through Large-Scale Production
TurboFil’s CrimpTech Series includes semi- and fully automatic machines.
Advertisement
TurboFil Packaging Machines, an equipment specialist dedicated to the design and development of liquid filling and assembly machines, has introduced a lineup of semi- and fully automatic vial crimping machines for R&D through scale-up and large-batch production.
The CrimpTech series handles vials in a variety of shapes and sizes. Using a novel design, each item is stopper-tamped prior to crimping to ensure a level seal. The units have low particle generation. Toolless changeover minimizes downtime.
For R&D, the CrimpTech Benchtop is a semi-automatic unit that can be placed under laminar flow hoods for aseptic and cleanroom applications. The CrimpTech Standalone is an automatic tabletop module; pre-stoppered vials enter and exit on a tray. The CrimpTech In-line is an automatic crimper that can connect to other units in a packaging line. It can process up to 50 containers per minute, with caps fed via a stainless steel vibratory feeder. For the two automatic systems, fast collet changeover allows different cap styles, and the star wheel can be easily changed for vials of various diameters.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement